Sarcoidosis - A Pipeline Analysis Report

Overview of the drug development pipeline for sarcoidosis

Sarcoidosis is an auto-immune aggressive systematic granulomatous disease and is characterized by effects on the lung. However, it can also affect almost all organs of the body. Also known as Besnier-Boeck-Schaumann disease, this is a rare disease due to which patches of red and swollen tissue called granulomas to develop in the organs of the body. In most of the cases, these granulomas disappear, either with or without treatment. The disease can appear suddenly and then disappear. In some cases, it can develop gradually and produce symptoms of sarcoidosis that can be seen during a person’s lifetime. Researchers believe that the disease is caused by an abnormal immune response and the inflammation occurs as the cells of the body’s immune system work together to protect an organ or tissue. The leading pharmaceutical companies are forecasted to invest heavily in R&D for the drug development for the treatment of sarcoidosis in the next few years.

According to our pipeline analysis report, most of the drug molecules in the pipeline are being developed for sarcoidosis. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.

Want a bigger picture? Try a FREE sample of this report now!

Pipeline report on drug development for sarcoidosis: Companies covered

This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of sarcoidosis. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug molecules discontinued by companies.

Some of the companies covered in this pipeline analysis report are:

• Araim Pharmaceuticals
• aTyr Pharma
• Auven Therapeutics
• Gotham Pharmaceuticals
• Novartis

Therapeutic assessment of the drug development pipeline for Sarcoidosis by route of administration

• Subcutaneous
• Oral
• Inhalation
• Intravenous
• Undisclosed

The subcutaneous route of administration (ROA) involves the delivery of the drug directly into the layer of the skin below the dermis and epidermis and in the oral technique, the drug molecules are delivered directly into the mouth cavity, which will have a more direct effect on the target cells. The inhalation route of administration is done by inhaling the drug molecules in the form of gas or vapor drug molecules for the treatment of sarcoidosis.

Therapeutic segmentation of the drug development pipeline for Sarcoidosis by modalities

• Small molecule
• Peptide
• Recombinant enzyme
• Monoclonal antibody
• Fusion protein

Small molecules are chemically manufactured active substances that can enter cells easily due to their low molecular weight (<900 Daltons). Inside the body, these molecules bind with specific biological macromolecules and act as an effector and alter the activity or function of the target.

According to this pipeline analysis report, most of the molecules that are currently in the drug development pipeline for sarcoidosis are being developed as small molecule drugs and many of these molecules are in the pre-clinical stage of development.

Key questions answered in the report include

• What are the drug molecules in the various development stages for sarcoidosis?
• What are the companies that are currently involved in the development of drug molecules for sarcoidosis?
• Insight into discontinued/inactive molecules with appropriate reasoning?
• What are the major regulatory authorities approving drugs in various regions?
• Detailed profiling of each active molecule

Technavio also offers customization on reports based on specific client requirement.